B cell Leukemia and Lymphoma are a group of diseases marked by proliferation of B lymphocytes.
Lentigen is developing a treatment for these diseases by genetic modification of T cells with Lentiviral vectors to express a chimeric T cell receptor targeted to the surface CD19 molecule, which is a marker for B cells.
A phase I clinical trial using LG740 is now open. View Details
